Elon Musk and his Neuralink company's attempt to begin testing brain chips in humans has been rejected by the FDA, according to a report by Reuters.
The request was submitted to the agency last year but according to Reuters, the FDA identified several problematic factors with the technology, including the chip's lithium battery and the potential for small wires to move to other areas of the brain.
"Neuralink doesn't appear to have the mindset and experience that's needed to get this to market anytime soon," Kip Ludwig, former program director for neural engineering at the U.S. National Institute of Health.
There was also a concern of whether or not the chip could be removed without inflicting damage to brain tissue.
What Exactly Is Neuralink?
Musk has claimed the technology could be life-changing for people suffering from paralysis, enabling them to communicate and walk, or it could help repair visual impairment in people.
The chip is supposed to process brain signals that are then transmitted to a device. While human trials for Neuralink have not commenced, there have been versions of the tech that reportedly had some success in animals. However, the company faced pushback and a probe from the U.S. Department of Agriculture after animal cruelty concerns were raised.
Last month Neuralink admitted that at least one monkey was euthanized because of a surgical complication.
Unpacking Jerome Powell’s surprise rate cut with Tematica Research CIO Chris Versace—what it signals, who wins, who loses, and what smart investors do now.
Ben & Jerry’s co-founder Jerry Greenfield is leaving the ice cream brand after 47 years. He says the freedom the company used to have to speak up on social issues has been stifled
The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy.
Oracle soars as it cashes in on the AI boom, Plus: Starbucks shares continue to fall under its new CEO, and does anybody actually want a new iPhone Air?
